In a report released today, Corinne Johnson from Goldman Sachs reiterated a Buy rating on Springworks Therapeutics (SWTX – Research Report). The company’s shares closed last Friday at $49.12.
According to TipRanks, Johnson is a 4-star analyst with an average return of 13.1% and a 58.75% success rate. Johnson covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Rhythm Pharmaceuticals, and Halozyme.
Currently, the analyst consensus on Springworks Therapeutics is a Strong Buy with an average price target of $57.80.
See the top stocks recommended by analysts >>
Based on Springworks Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $79.44 million. In comparison, last year the company had a GAAP net loss of $72.39 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Springworks Therapeutics (SWTX) Company Description:
Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm’s products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.
Read More on SWTX:
- SpringWorks Therapeutics to Present at Upcoming Investor Conferences
- SpringWorks Therapeutics CDO Resigns, Assumes Advisory Role
- SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- SpringWorks Therapeutics price target raised to $47 from $41 at Barclays
- 3 Best Stocks to Buy Now, 1/18/2024, According to Top Analysts
